Agenus (AGEN) Misses Q2 EPS by 38c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. DPZ
2. NVDA
3. BAC
4. DRS
5. GS
6. AVAV
7. ACI
8. UNH
9. ORCL
10. LQDA

Go back to Agenus (AGEN) Misses Q2 EPS by 38c

Agenus Reports Second Quarter 2015 Financial Results

July 23, 2015 7:00 AM EDT

Corporate Update Conference Call at 11 am ET Today

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (NASDAQ: AGEN), an immunology company discovering and developing innovative treatments for cancers and other diseases, today announced its financial results for the second quarter ended June 30, 2015.

During the second quarter, we made meaningful advances across all areas of our business which include our proprietary clinical-stage programs, our immuno-oncology portfolio, strategic acquisitions and our balance sheet, said Dr. Garo H. Armen, Chairman and CEO of Agenus. Of note, we presented updated Phase 2 results... More